CTMC evaluated the Xiogenix Ares X20+ automated fill-finish system for tumor-infiltrating lymphocyte (TIL) therapy manufacturing, comparing its performance with manual processes. Explore the study methodology and findings in our white paper.
Read the White Paper: ARES X20+ Study
Authors
Donastas Sakellariou-Thompson, Lothar Lauterboeck, Tamara Griffiths, Aemilia Katzinski, Anindita Ravindran,
Jane Zulovich, Katrina Adlerz, Priya Balasubramanian, Chantale Bernatchez, Marie-Andrée Forget